The aforementioned studies supporting the antifibrotic potential of PDE4 inhibitors led us to further investigate the efficacy of this class of medications in a murine model of lung fibrosis that results from a targeted insult to the type II alveolar epithelium (Sisson et al. This evidence concerns the gene PDE4A and pulmonary fibrosis.